
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
ELINZANETANT IN MANAGING MENOPAUSAL SYMPTOMS: PHARMACODYNAMICS, SAFETY AND ADVANTAGES OVER HORMONE THERAPY
Yazhisai M.*, Sakthi Poorani K., Rekha S.
Abstract Menopause is associated with vasomotor symptoms (VMS), including hot flashes and sleep disturbances, affecting up to 80% of women with hot flashes and 60% with sleep diturbance, respectively. For 10–20% of women, symptoms are severe and impair quality of life. While hormone replacement therapy (HRT) is the most common treatment, its use is limited by contraindications such as vaginal bleeding, breast cancer, and endometrial hyperplasia. Becausof these limitations, there is a growing need for effective non-hormonal alternatives. Elinzanetant (NT-814), branded as Lynkuet™, is a nonhormonal dual NK-1 and NK-3 receptor antagonist for menopausal VMS. As the first dual NK-1/NK-3 receptor antagonist, it targets hypothalamic pathways in thermoregulation. Elinzanetant was approved by Health Canada on July 23, 2025, followed by approval from the U.S. FDA later that year. Clinical efficacy was demonstrated in the Phase III OASIS-1 and OASIS-2 trials (n=796), while long-term safety was evaluated across OASIS-1, OASIS-2, and OASIS-3 studies (n=1,420). These trials showed significant reductions in hot flash frequency and severity with favorable tolerability. This review examines its pharmacodynamics, safety, pharmacokinetics, and therapeutic advantages over hormone therapy. Keywords: Elinzanetant, Menopause, Vasomotor symptoms, Hot flashes, Thermoregulation, Hormone Replacement Therapy, Nk-1/Nk-3 receptor antagonist, Non-Hormonal Therapy. [Full Text Article] [Download Certificate] |
